AURA Overview

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is19.33 USD with a low forecast of 13.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aura Biosciences Inc revenue for the last quarter amounts to -27.24M USD, decreased -2.05

Aura Biosciences Inc. EPS for the last quarter amounts to -20645000.00 USD, decreased -14.87

Aura Biosciences Inc (AURA) has 113 emplpoyees as of May 11 2026.

Today AURA has the market capitalization of 926.52M USD.